BANK VONTOBEL/CALL/MODERNA/125/0.1/21.06.24 | Market Closed - Deutsche Boerse AG 19:02:35 14/06/2024 BST | ||
| 1.34 EUR | -33.99% |
|
| Current month | -24.29% | ||
| 1 month | +55.81% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 1.34 | -33.99% |
| 13/06/24 | 2.03 | -11.74% |
| 12/06/24 | 2.3 | +4.55% |
| 11/06/24 | 2.2 | +0.46% |
| 10/06/24 | 2.19 | -8.37% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 07:02 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VM3MZE |
| ISIN | DE000VM3MZE6 |
| Date issued | 06/10/2023 |
| Strike | 125 $ |
| Maturity | 21/06/2024 (6 Days) |
| Parity | 10 : 1 |
| Emission price | 1.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.11 € |
|---|---|
| Lowest since issue | 0.204 € |
| Spread | 0.02 € |
| Spread % | 1.37% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140
USD
Average target price
145.2
USD
Spread / Average Target
+3.67%
- Stock Market
- Warrants
- Warrant
